<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 1997
SUGEN, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-24814 13-3629196
(State of jurisdiction) (Commission File No.) (IRS Employer
Identification No.)
351 Galveston Drive
Redwood City, California 94063
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 306-7700
<PAGE>
Item 5. Other Events.
- -------------------------------------------------------------------------------
On November 7, 1997, SUGEN, Inc. (the "Company") announced the public
offering of 2,000,000 shares of its Common Stock at a price of $16.00 per
share. In addition, the Company granted the underwriters an option to
purchase an additional 300,000 shares of Common Stock to cover
over-allotments, if any.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
- --------------------------------------------------------------------------------
(a) Financial Statements.
None.
(b) Pro Forma Financial Information.
None.
(c) Exhibits.
99.1 Press Release, titled "SUGEN, Inc. Announces $32 Million Follow-On
Offering," dated November 7, 1997.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SUGEN, Inc.
Dated: November 18, 1997 By: /s/ Christine E. Gray-Smith
-------------------------------
Christine E. Gray-Smith
Vice President, Finance
(Principal Financial Officer)
<PAGE>
EXHIBIT 99.1
(BW) SUGEN, Inc. Announces $32 Million Follow-On Offering
REDWOOD CITY, Calif.--(BW HealthWire)--Nov. 7, 1997--SUGEN, Inc.
(NASDAQ:SUGN) today announced the public offering of 2,000,000 shares of Common
Stock at a price of $16.00 per share.
The company also granted the Underwriters of the offering an option to
purchase 300,000 additional shares to cover over-allotments. The offering was
lead managed by Hambrecht & Quist LLC, with Lehman Brothers Inc. and UBS
Securities LLC co-managing. These securities are offered only by means of a
prospectus and this announcement is neither an offer to sell nor a solicitation
of any offer to buy.
SUGEN, Inc. is a biopharamceutical company focusing on the development of
new classes of small molecule drugs which interact in a specific manner with
different members of the tyrosine kinase, serine-threonine kinase and tyrosine
phosphatase families of signal transduction molecules, and their signalling
pathways. These pathways are involved in a number of human diseases including
cancer and diabetes, as well as disorders of the body's immune defenses and
neurological systems.
SUGEN currently has three products in clinical trials which include SU101
(a PDGF receptor inhibitor) in Phase II studies for the treatment of malignant
gliomas and other cancers; SU5271 (an EGF receptor inhibitor) in Phase I studies
for the treatment of psoriasis; and SU5416 (a Flk-1/KDR angiogenesis inhibitor)
in Phase I studies for the treatment of solid tumors and tumor metastases. The
Company has research and development collaborations with Zeneca, ASTA Medica and
Allergan.
Copies of the final prospectus relating to these securities may be obtained
from Hambrecht & Quist LLC, One Bush Street, San Francisco, CA 94104, phone:
415/439-3423; Lehman Brothers Inc., Three World Financial Center, New York, NY
10285, phone: 516/254-7106; or UBS Securities LLC, 299 Park Avenue, New York, NY
10171, phone: 212/821-4504.
Additional written materials and press releases regarding SUGEN are
available through the SUGEN Fax-On-Demand Information Service by dialing
888/329-4699.
Contact: SUGEN, Inc.
D. Kevin Kwok, 650/306-7700
[email protected]
